Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Eurican L4 is an inactivated immunological veterinary vaccine designed for the active immunisation of dogs against leptospirosis. It contains inactivated strains from four key Leptospira serogroups and serovars—Canicola (strain 16070), Icterohaemorrhagiae (strain 16069), Grippotyphosa (Grippo Mal 1540), and Australis/Bratislava (strain 16785). The vaccine aims to prevent or reduce mortality, clinical signs, infection, bacterial excretion, renal carriage, and renal lesions caused by these Leptospira species. It is administered as a subcutaneous injection starting at seven weeks of age with a booster after four weeks and then annually. The product does not contain an adjuvant[1][2][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Eurican L4.